Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT03449654
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 102 participants
- Registry
-
NCT03449654
-
- Other papers using this trial's data
- Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
- Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT03449654. Randomized; double masking; primary purpose prevention. Start 2017-10-26 (actual); primary completion 2019-08-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
- Acronym
- LIRAFLAME
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Placebo (for liraglutide)
- Lead sponsor
- Steno Diabetes Center Copenhagen
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
Record details
- Record id
cardio:ct-nct03449654- Content hash
1d4126bf830354f3301d126b644b115c623ebb64ec20e0a013df828967975aa2